| 105176-2 | Living Arrangements FASI:-:RptPeriod:^Patient:-:CMS Assessment | 4 |
| 105194-5 | Risankizumab Ab pnl SerPl | 3 |
| 105201-8 | MDS v3.0 - RAI v1.19.1 - Nursing home part A PPS discharge (NPE) item set:-:RptPeriod:^Patient:-:CMS Assessment | 12 |
| 105202-6 | fentaNYL+Norfentanyl pnl Bld LC/MS/MS | 3 |
| 105258-8 | Fam His Incarce 281001 | 20 |
| 105285-1 | Neutrophil Ab screen pnl SerPl | 4 |
| 105371-9 | AQI proto 290101 | 16 |
| 105456-8 | Anemia eval pnl SerBld | 11 |
| 105457-6 | Lysophosphatidylcholines pnl DBS | 5 |
| 105458-4 | Lyso & perox sto disorer pnl DBS | 13 |
| 105459-2 | Copper pnl SerPl | 4 |
| 105485-7 | Healthcare comms proto 281101 | 15 |
| 105506-0 | Health num proto 280201 | 21 |
| 105519-3 | Lipid profile proto | 14 |
| 105578-9 | PhenX envi ust proto 290401 | 18 |
| 105750-4 | Lactose challenge meth Pnl ExG | 10 |
| 105751-2 | Lactose challenge panel-H ExG | 16 |
| 105848-6 | CRP proto 660601 | 16 |
| 106053-2 | Rf Igm & Iga pnl SerPl | 3 |
| 106054-0 | PBC comprehensive Ab pnl SerPl | 9 |
| 106055-7 | SP100 and GP210 Ab.IgG pnl SerPl | 3 |
| 106057-3 | Beta-Amyloid 1-42 and 1-40 pnl CSF | 4 |
| 106058-1 | CT + NG + TV rRNA Pnl Vagina NAA+probe | 4 |
| 106059-9 | Enteric parasite pnl Stl NAA+probe | 4 |
| 106060-7 | Hep B and C virus Ab panel Ser NAA+probe | 5 |
| 106061-5 | Enteric bacteria pnl Stl NAA+probe | 9 |
| 106062-3 | Enteric path pnl Stl NAA+probe | 19 |
| 106204-1 | Batch pnl Medication | 2 |
| 106205-8 | Performing lab pnl | 2 |
| 106220-7 | Ventilator Liberation Rate:-:RptPeriod:^Patient:-:CMS Assessment | 6 |
| 106301-5 | Wake Forest Trust Scale SF | 7 |
| 106345-2 | NICHQ Vanderbilt Assessment Scale - Parent Informant:-:6Mo:^Patient:-: | 65 |
| 106416-1 | Hester Davis fall risk scale | 3 |
| 106418-7 | Three-Item Loneliness scale:-:Pt:^Patient:-:Three-Item Loneliness Scale | 5 |
| 106423-7 | 6-item Transportation Security Index:-:30D:^Patient:-:TSI-6 | 9 |
| 106444-3 | West Haven-Yale multidimensional pain inventory:-:Pt:^Patient:-:WHYMPI | 5 |
| 106445-0 | Pre-Evaluation Questions:-:Pt:^Patient:-:WHYMPI | 2 |
| 106448-4 | Part 1:-:Pt:^Patient:-:WHYMPI | 21 |
| 106470-8 | Part 2:-:Pt:^Patient:-:WHYMPI | 15 |
| 106486-4 | Part 3:-:Pt:^Patient:-:WHYMPI | 19 |
| 106506-9 | Opiates pnl Ur LC/MS/MS | 13 |
| 106517-6 | Functional assessment standardized items (FASI) - v1.2:-:RptPeriod:^Patient:-:CMS Assessment | 3 |
| 106521-8 | Subepit auto blis pnl SerPl | 4 |
| 106523-4 | Outcome and assessment information set (OASIS) form - version E1 - Start of Care:-:RptPeriod:^Patient:-:CMS Assessment | 15 |
| 106524-2 | Outcome and assessment information set (OASIS) form - version E1:-:RptPeriod:^Patient:-:CMS Assessment | 7 |
| 106525-9 | Outcome and assessment information set (OASIS) form - version E1 - Resumption of Care:-:RptPeriod:^Patient:-:CMS Assessment | 15 |
| 106526-7 | Outcome and assessment information set (OASIS) form - version E1 - Death at Home:-:RptPeriod:^Patient:-:CMS Assessment | 4 |
| 106527-5 | Outcome and assessment information set (OASIS) form - version E1 - Transfer to an Inpatient Facility:-:RptPeriod:^Patient:-:CMS Assessment | 5 |
| 106528-3 | Outcome and assessment information set (OASIS) form - version E1 - Follow Up:-:RptPeriod:^Patient:-:CMS Assessment | 5 |
| 106529-1 | Outcome and assessment information set (OASIS) form - version E1 - Discharge from Agency:-:RptPeriod:^Patient:-:CMS Assessment | 15 |